Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Mar 14;18:128–138. doi: 10.1016/j.ebiom.2017.03.019

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Fig. 2 — SRT1720 inhibits cAMP-specific phosphodiesterases by competing with cAMP.

(A) Cyclic AMP levels in C2C12 myotubes were measured 30 min after treatment with the indicated concentrations of SRT1720. All values are given as mean ± s.e.m. *p < 0.05; **, p < 0.01. (B) Cyclic AMP levels in C2C12 myotubes were measured at the indicated times after treatment with 2.5 μM SRT1720. All values are given as mean ± s.e.m. *p < 0.05; **, p < 0.01. (C) The inhibitory effect of SRT1720 on recombinant PDE1–5 is shown. All values are given as mean ± s.e.m. (D) Velocity of recombinant PDE3 activity as a function of cAMP and SRT1720 concentration. All values are given as mean ± s.e.m. (E) Lineweaver-Burk plot of panel (D). (F) Recombinant PDE3 was photoaffinity-labeled with the fluorescent cAMP analog 8-azido-[DY-547]-cAMP in the presence of increasing concentrations of SRT1720 or cAMP. Quantification of 8-azido-[DY-547]-cAMP bound to PDE3 is shown. All values are given as mean ± s.e.m. (G) Inhibitory effects of SRT1720 (2 μM) and Rolipram (2 μM) on recombinant PDE4 activity as a function of cAMP concentration is shown. All values are given as mean ± s.e.m.